12407 N. MOPAC EXPY., AUSTIN, TX
Rein Therapeutics Enters $2.3M Private Placement with Institutional Investors
Director Resignation - Manuel C. Alves Aivado Steps Down from Board
Rein Therapeutics Enters $2.5M Securities Purchase Agreement with Funicular
Rein Therapeutics Terminates Pre-Paid Advance and Standby Equity Agreements
Other Events
Rein Therapeutics Enters $6 Million Pre-Paid Advance Agreement with Yorkville
Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Q3
Q2
Q1
Amended Annual Report
FY 2024
Notice of Late Filing for Annual Report
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Free Writing Prospectus